Neurology 2000;55:1714-1718
© 2000 American Academy of Neurology
Articles
Whole brain volume changes in patients with progressive MS treated with cladribine
M. Filippi, MD,
M. Rovaris, MD,
G. Iannucci, MD,
S. Mennea,
M. P. Sormani, PhD and
G. Comi, MD
From the Neuroimaging Research Unit (Drs. Filippi, Rovaris, Iannucci, and Sormani, and S. Mennea) and Clinical Trials Unit (Dr. Comi), Department of Neuroscience, Scientific Institute Ospedale San Raffaele, University of Milan, Italy.
Address correspondence and reprint requests to Dr. Massimo Filippi, Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute Ospedale San Raffaele, Via Olgettina, 60, 20132 Milan, Italy; e-mail: m.filippi{at}hsr.it
Article abstract
OBJECTIVE: To compare changes in whole brain volume measured using MRI scans in patients with progressive MS enrolled in a double-blind, placebo-controlled trial assessing the efficacy of two doses of cladribine (0.7 and 2.1 mg/kg) and to assess the correlations between change in whole brain volume and change in other conventional MRI measures.
BACKGROUND: Measuring brain parenchymal volumes is an objective and reliable surrogate for the destructive pathologic process in MS. The dynamics and the mechanisms of tissue loss in progressive MS are unclear.
METHODS: Whole brain volumes were measured using postcontrast T1-weighted scans with 3 mm slice thickness from 159 patients with progressive MS (70% secondary progressive and 30% primary progressive) enrolled in a double-blind, placebo-controlled trial of 12-month duration.
RESULTS: Whole brain volumes were similar in the placebo and cladribine-treated patients on the baseline scans. A significant decrease of brain volume over time was observed both in the entire population of patients (p = 0.001) and in the placebo patients in isolation (p = 0.04). No significant treatment effect of either dose of cladribine on brain volume changes over time was found. In the 54 patients who received placebo, the change in brain volume was not significantly correlated with other MRI measures at baseline (enhancing lesion number and volume and T2-hyperintense and T1-hypointense lesion volumes) or at follow-up (cumulative number of enhancing lesions and absolute and percentage changes of enhancing T2- and T1-hypointense lesion volumes).
CONCLUSIONS: This study shows in a large cohort of patients that brain parenchymal loss occurs, even over a short period of time, in progressive MS and that cladribine is not able to alter this process significantly. It also suggests that MRI-visible inflammation and new lesion formation has a marginal role in the development of brain atrophy in patients with progressive MS.
This article has been cited by other articles:
|
|
|
|
 
R. Zivadinov, A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K. Racke, M. G. Dwyer, E. M. Frohman, and O. Khan
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
Neurology,
July 8, 2008;
71(2):
136 - 144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.S. Meier, H.L. Weiner, and C.R.G. Guttmann
MR Imaging Intensity Modeling of Damage and Repair In Multiple Sclerosis: Relationship of Short-Term Lesion Recovery to Progression and Disability
AJNR Am. J. Neuroradiol.,
November 1, 2007;
28(10):
1956 - 1963.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J H Simon
Brain atrophy in multiple sclerosis: what we know and would like to know
Multiple Sclerosis,
November 1, 2006;
12(6):
679 - 687.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A Brousil, R. J Roberts, and A. L Schlein
Cladribine: An Investigational Immunomodulatory Agent for Multiple Sclerosis
Ann. Pharmacother.,
October 1, 2006;
40(10):
1814 - 1821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Richert, T. Howard, J. A. Frank, R. Stone, J. Ostuni, J. Ohayon, C. Bash, and H. F. McFarland
Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis
Neurology,
February 28, 2006;
66(4):
551 - 556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans, M. Clanet, E. W. Radue, L. Kappos, and for the European IFNss-1a in Relapsing MS Dose Com
Rate of brain atrophy in relapsing MS decreases during treatment with IFN{beta}-1a
Neurology,
January 25, 2005;
64(2):
236 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Cohen and J. P. Antel
Does interferon beta help in secondary progressive MS?
Neurology,
November 23, 2004;
63(10):
1768 - 1769.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Filippi, M. A. Rocca, E. Pagani, G. Iannucci, M. P. Sormani, F. Fazekas, S. Ropele, O. R. Hommes, and G. Comi
European Study on Intravenous Immunoglobulin in Multiple Sclerosis: Results of Magnetization Transfer Magnetic Resonance Imaging Analysis
Arch Neurol,
September 1, 2004;
61(9):
1409 - 1412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Boneschi, M. Rovaris, G. Comi, and M. Filippi
The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials
Multiple Sclerosis,
August 1, 2004;
10(4):
341 - 347.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Sharma, M. P. Sanfilipo, R. H. B. Benedict, B. Weinstock-Guttman, F. E. Munschauer III, and R. Bakshi
Whole-Brain Atrophy in Multiple Sclerosis Measured by Automated versus Semiautomated MR Imaging Segmentation
AJNR Am. J. Neuroradiol.,
June 1, 2004;
25(6):
985 - 996.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Hartman and P. Hentosh
The Antileukemia Drug 2-Chloro-2'-deoxyadenosine: An Intrinsic Transcriptional Antagonist
Mol. Pharmacol.,
January 1, 2004;
65(1):
227 - 234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Nash, J. D. Bowen, P. A. McSweeney, S. Z. Pavletic, K. R. Maravilla, M.-s. Park, J. Storek, K. M. Sullivan, J. Al-Omaishi, J. R. Corboy, et al.
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis
Blood,
October 1, 2003;
102(7):
2364 - 2372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Pelletier, S J Nelson, J Oh, J P Antel, M Kita, S S Zamvil, and D E Goodkin
MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy
J. Neurol. Neurosurg. Psychiatry,
July 1, 2003;
74(7):
950 - 952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Inglese, J.H.T.M. van Waesberghe, M. Rovaris, K. Beckmann, F. Barkhof, D. Hahn, L. Kappos, D.H. Miller, C. Polman, C. Pozzilli, et al.
The effect of interferon {beta}-1b on quantities derived from MT MRI in secondary progressive MS
Neurology,
March 11, 2003;
60(5):
853 - 860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rovaris, M. A Rocca, and M. Filippi
Magnetic resonance-based techniques for the study and management of multiple sclerosis
Br. Med. Bull.,
March 1, 2003;
65(1):
133 - 144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Miller, F. Barkhof, J. A. Frank, G. J. M. Parker, and A. J. Thompson
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance
Brain,
August 1, 2002;
125(8):
1676 - 1695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Drachman
Hat size, brain size, intelligence, and dementia: What morphometry can tell us about brain function and disease
Neurology,
July 23, 2002;
59(2):
156 - 157.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Filippi and R. I. Grossman
MRI techniques to monitor MS evolution: The present and the future
Neurology,
April 23, 2002;
58(8):
1147 - 1153.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rovaris, G. Comi, M. A. Rocca, J. S. Wolinsky, and M. Filippi
Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications
Brain,
September 1, 2001;
124(9):
1803 - 1812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Gasperini, M Rovaris, M P Sormani, S Bastianello, C Pozzilli, G Comi, and M Filippi
Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis
Multiple Sclerosis,
February 1, 2001;
7(1):
27 - 31.
[Abstract]
[PDF]
|
|
|
|
